Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Axsome Therapeutics (AXSM) FCF Margin (2022 - 2025)

Historic FCF Margin for Axsome Therapeutics (AXSM) over the last 4 years, with Q3 2025 value amounting to 0.58%.

  • Axsome Therapeutics' FCF Margin rose 184500.0% to 0.58% in Q3 2025 from the same period last year, while for Sep 2025 it was 18.07%, marking a year-over-year increase of 211800.0%. This contributed to the annual value of 33.36% for FY2024, which is 204700.0% up from last year.
  • According to the latest figures from Q3 2025, Axsome Therapeutics' FCF Margin is 0.58%, which was up 184500.0% from 21.62% recorded in Q2 2025.
  • In the past 5 years, Axsome Therapeutics' FCF Margin ranged from a high of 0.58% in Q3 2025 and a low of 382.97% during Q2 2022
  • For the 4-year period, Axsome Therapeutics' FCF Margin averaged around 78.29%, with its median value being 39.22% (2023).
  • As far as peak fluctuations go, Axsome Therapeutics' FCF Margin surged by 2641700bps in 2023, and later tumbled by -651900bps in 2024.
  • Axsome Therapeutics' FCF Margin (Quarter) stood at 113.84% in 2022, then skyrocketed by 63bps to 42.46% in 2023, then soared by 48bps to 22.09% in 2024, then skyrocketed by 103bps to 0.58% in 2025.
  • Its FCF Margin was 0.58% in Q3 2025, compared to 21.62% in Q2 2025 and 35.99% in Q1 2025.